SecBot SecBot
SECBOTREPLAY Home › Report › TLSI

TLSI · Q3 revenue +11% YoY, guide cut

TriSalus Life Sciences, Inc. · 8-K filed Nov 10, 2026 at 08:06 ET

At the news

BEARISHIMPACT 6/10

8-K filed Nov 10, 2026 at 08:06 ET

TriSalus Life Sciences reported Q3 2026 revenue of $12.9M (+11.3% YoY), above the $14.0M consensus, but revised full-year 2026 revenue guidance down to $46M-$48M (2-6% growth vs 2025), well below the prior $54M-$57M range. CMS finalized favorable 2027 reimbursement rate increases for PEDD procedures, but the guidance cut signals slower-than-expected commercial ramp.

  • Q3 2026 revenue $12.9M, +11.3% YoY from $11.6M
  • Full-year 2026 revenue guidance revised to $46M-$48M from prior $54M-$57M
  • GAAP diluted EPS -$0.15 vs -$0.96 YoY; consensus was -$0.13
  • Gross margin 86.2% vs 83.5% YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access